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Abstract
Background: Congenital cytomegalovirus (CMV) infection is the most common intrauterine infection in the United States
disproportionately affecting minority races and those of lower socio-economic class. Despite its importance there is little
information on the burden of congenital CMV-related mortality in the US. To measure congenital CMV-associated mortality
in the US and assess possible racial/ethnic disparities, we reviewed national death certificate data for a 17-year period.
Methods: Congenital CMV-associated deaths from 1990 through 2006 were identified from multiple-cause-coded death
records and were combined with US census data to calculate mortality rates.
Results: A total of 777 congenital CMV-associated deaths occurred over the 17-year study period resulting in 56,355 years of
age-adjusted years of potential life lost. 71.7% (557) of congenital CMV-associated deaths occurred in infants (age less than
1 year). Age-adjusted mortality rates stratified by race/ethnicity revealed mortality disparities. Age-adjusted rate ratios were
calculated for each racial/ethnic group using whites as the reference. Native Americans and African Americans were 2.34
(95% CI, 2.11–2.59) and 1.89 (95% CI, 1.70–2.11) times respectively, more likely to die from congenital CMV than whites.
Asians and Hispanics were 0.54 (95% CI, 0.44–0.66) and 0.96 (95% CI, 0.83–1.10) times respectively, less likely to die from
congenital CMV than whites.
Conclusions/Significance: Congenital CMV infection causes appreciable mortality in the US exacting a particular burden
among African Americans and Native Americans. Enhanced surveillance and increased screening are necessary to better
understand the epidemiology of congenital CMV infection in addition to acceleration of vaccine development efforts.
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Introduction
Cytomegalovirus (CMV) is a member of the herpesviridae
family of viruses, which cause latent and reactivated viral infection.
Humans are the main reservoir of human CMV (human herpes
virus 5) [1,2]. CMV is shed in saliva, urine, breast milk, semen and
blood and is spread via direct contact (non-sexual and sexual) [3].
CMV can be vertically transmitted from a mother with primary or
secondary infection to her unborn child with consequences
ranging from asymptomatic infection to lifelong disability to
severe disease resulting in fetal or neonatal death. Secondary
infection may be the result of reactivation from a primary infection
or new infection. While the majority of cases of symptomatic
congenital disease occur following primary maternal infection,
secondary recurrent maternal infection can also lead to disease
[2,4].
One of the most important risk factors for primary CMV
infection during pregnancy is prolonged exposure to young
children since CMV infected children under age two will secrete
virus in the saliva and urine for an average of 24 months [5,6].
This may explain the risk of primary CMV infection during
pregnancy in multiparious women, especially in women with
children in day care as well as the increased risk in women of
childbearing ages working in day care facilities [3,7].
Sexual contact is another risk factor for maternal infection with
vertical transmission. Young maternal age, greater numbers of
sexual partners, abnormal cervical cytology, and having a sexually
transmitted infection during pregnancy are all associated with
CMV seropositivity [3,8–10]. There is limited evidence suggesting
presence of a sexually transmitted infection, including HIV, may
increase the risk of vertical CMV transmission from mother to
fetus/infant [11–14].
Congenital CMV infection is the most common intrauterine
infection in the United States with direct annual costs of over one
billion dollars [15,16]. The live birth prevalence of congenital
CMV infection in the developed world is 0.6–0.7% [12]. Of those
infected, 10% are symptomatic as neonates (,30 days of age) with
the majority surviving the initial infection; however, greater than
90% develop long-term neurological sequelae including sensori-
neural hearing loss (unilateral and bilateral), mental retardation,
cerebral palsy, and impaired vision from chorioretinitis [4,9,17].
Of the remaining 90% of congenital CMV infections that are
asymptomatic, approximately 10–15% will later develop long-
term neurological sequelae [9,17]. Congenital CMV infection
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disability annually [15]. There are more cases of permanent
disability due to congenital CMV than other, better known,
congenital conditions such as Downs syndrome, fetal alcohol
syndrome and spina bifida [11,18].
Congenital CMV has been labeled as one of the Neglected Infection
of Poverty in the United States as it is poorly known by the US
public-health community, it has a disproportionate impact on the
health of the poorest Americans, and it promotes poverty via its
negative impact on child development and pregnancy outcomes
[19,20].
Despite its importance, there is a lack of information about
congenital CMV-related deaths in the US. Information on
congenital CMV mortality is important to better understand the
burden of disease and evaluate the effectiveness of public health
interventions. Population-based mortality data has been used to
investigate other infectious diseases, but these data have not yet
been used in published congenital CMV research [21–24]. We
examined national mortality data to assess the burden and
demographics of congenital CMV-associated mortality in the
United States from 1990–2006.
Methods
Multiple-cause-of-death data from US death certificates from
the National Center for Health Statistics (NCHS) were analyzed
for the years 1990–2006 [25]. These death certificates contain
basic demographic information for each decedent, including age,
sex, race/ethnicity and state of residence. In addition to
designating underlying causes, the physician or coroner complet-
ing the death certificate may list up to 20 conditions that are
believed to have contributed in some way to the death of an
individual. Each of these conditions is coded on the basis of the
International Classification of Diseases (ICD) system for the year in
which the death occurred (ICD, Ninth Revision [ICD-9] for the
period 1990–1998 and ICD, Tenth Revision [ICD-10] for the period
1999–2006).
We defined cases as US resident deaths having an ICD-9 code
of 771.1 (‘‘Congenital cytomegalovirus infection, Congenital
cytomegalic inclusion disease’’) or an ICD-10 code of P35.1
(‘‘Congenital cytomegalovirus infection’’) listed as an underlying or
contributing cause on the death record.
Mortality rates were calculated using bridged-race population
estimates derived from US census data and were subsequently age-
adjusted with weights from the 2000 US standard population data
[26–28]. Mortality rates for race/ethnicity, sex, age, year and
State were calculated with aggregated data from all years of our
study to ensure stable rates. Race/ethnicity was divided into 5
categories: non-Hispanic white, non-Hispanic black, Hispanic,
Asian/Pacific Islander, and Native American. Analysis by age
included infants (,1 year), neonates (,28 days), postneonates (28–
364 days), #5years and .5 years. For our geographic analysis, we
divided the 50 states into 4 major regions according to US census
divisions [29]. All calculations were performed with SAS, version
9.1.
Results
We identified 777 congenital CMV-associated deaths during the
period 1990–2006, representing 0.002% of the 39,755,734 total
deaths among USresidents.43.8%(340)of deaths were inmalesand
56.2% (437) were in females. 67.6% (525) of the deaths identified
congenital CMV as an underlying cause and 32.4% (252) identified
it as a contributing cause. Neonates (age ,28 days) represented
41.1% (319 deaths) of all congenital CMV deaths. Postneonates (age
28–364 days) accounted for 30.6% (238 deaths) of all congenital
CMV deaths. Infants (age ,1 year), which include both neonates
and postneonates, represented 71.7% (557) of all congenital CMV
deaths. Children (age #5 years) accounted for 83.3% (647) of all
congenital CMV deaths. The final 16.7% (130) congenital CMV
deaths occurred in those age .5. The 557 congenital CMV-
associated deaths in infants during the period 1990–2006 represents
0.11% of the 514,930 total deaths among US infants.
The overall crude mortality rate associated with congenital
CMV was 0.17 per 1 million persons annually (95% CI, 0.15–
0.18), and after adjustment for age, changed slightly to 0.16 per 1
million persons annually (95% CI, 0.15–0.17) [TABLE 1]. The
age-adjusted years of potential life lost for all congenital CMV
deaths was 56,355 years. The infant mortality rate associated with
congenital CMV was 8.34 per 1 million infants annually (95% CI,
7.65–9.04).
The age-adjusted mortality rates stratified by race/ethnicity
reveal mortality disparities. Native Americans represented 1.9%
(15) of all congenital CMV deaths and had the highest age
adjusted mortality rate at 0.34 per 1 million annually (95% CI,
0.17–0.51). African Americans accounted for 25.6% (199) of all
congenital CMV deaths with an age adjusted mortality rate of 0.27
per 1 million annually (95% CI, 0.23–0.31). Whites represented
54.7% (425) of all congenital CMV deaths with an age adjusted
mortality rates of 0.14 per 1 million annually (95% CI, 0.13–0.16).
Hispanics represented 15.8% (123) of all congenital CMV deaths
with an age adjusted mortality rate of 0.14 per 1 million annually
(95% CI, 0.11–0.16). Asians represented 1.9% (15) of all
congenital CMV deaths and had the lowest age adjusted mortality
rate at 0.08 per 1 million annually (95% CI, 0.04–0.12).
Adjusted rate ratios were calculated for each racial/ethnic
group using whites as the reference [TABLE 2]. Native Americans
and African Americans were 2.34 (95% CI, 2.11–2.59) and 1.89
(95% CI, 1.70–2.11) times respectively, more likely to die from
congenital CMV than whites. Asians and Hispanics were 0.54
(95% CI, 0.44–0.66) and 0.96 (95% CI, 0.83–1.10) times
respectively, less likely to die from congenital CMV than whites.
Congenital CMV-associated mortality varied across the 4 major
geographic regions of the United States. From 1990–2006, the
Author Summary
Cytomegalovirus (CMV) is a member of the herpes family
of viruses, which is transmitted by sexual and non-sexual
contact. Human CMV causes a wide variety of infection
and illness in healthy adults, in those with compromised
immune systems (such as AIDS), in those with cardiovas-
cular disease, and in pregnant women who can pass the
infection to their unborn child (congenital CMV). Treat-
ment options for congenital CMV are limited and no
effective vaccine to protect against CMV currently exists.
Previous studies have demonstrated that African Ameri-
cans and Mexican Americans are at an increased risk for
congenital CMV infections. In this study, the authors
examined death certificate data of US Residents from
1990–2006 in which congenital CMV was listed as one of
the diagnoses at death. The analysis demonstrated that
there is a significant burden of congenital CMV deaths in
infants (,1 year old) with African Americans and Native
Americans overrepresented. This study helps quantify
congenital CMV deaths among US residents and adds
further support to the importance of funding CMV vaccine
research.
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adjusted mortality rate of 0.10 deaths per 1 million persons
annually. The West, Midwest and South had age adjusted
mortality rates of 0.16, 0.17 and 0.19 deaths per 1 million persons
annually respectively.
The annual number of deaths from congenital CMV ranged
from 36 to 56 deaths with no observed trend over the study period.
The number of deaths per month from congenital CMV ranged
from 58 to 83 with no obvious seasonal trend noted over the study
period.
Discussion
Congenital CMV causes appreciable mortality in the US and
demonstrates important racial/ethnic disparities with African
Americans and Native Americans experiencing a disproportionate
burden of mortality. Almost three out of every four Congenital
CMV deaths occurs during infancy. The greatest Congenital
CMV mortality is found in the US South, while the US Northeast
experiences the lowest mortality.
The observed mortality disparities are in agreement with the
literature demonstrating disparities in CMV antibody seropreva-
lence among pregnant US women. Staras et al. demonstrated that
of seronegative women in the US at age fifteen, 38.1% of whites
will seroconvert by age forty-four while 87.3% of African
Americans and 63.6% of Mexican Americans will seroconvert
by age forty-four [30]. The racial/ethnic disparities in congenital
CMV-associated mortality also fit within the context of overall
socio-economic disparities in US infant and childhood mortality
[31,32]. Baseline racial/ethnic health disparities and access
inequalities likely play a further role in driving this congenital
CMV-associated mortality disparity.
In the developing world, CMV is acquired early in life where
seroprevalence exceeds 90% by adulthood [1]. The improved, yet
varied, living conditions of the developed world have lead to the
delayed acquisition of CMV in the US population with those of a
minority race and/or lower socioeconomic status experiencing a
greater burden of primary infection during the childbearing years
(15–44) resulting in an overrepresentation of CMV infection
amongst their newborns [3,8–10,12,33–36].
Control of congenital CMV requires expanded surveillance
activities and further elucidation of the epidemiology of CMV to
promote vaccine development [2,4,20]. The Institute of Medicine
placed CMV in its highest priority group for vaccine development
based on an analysis of the costs of disease and impact on quality
adjusted life years [16]. Despite this, it is claimed that CMV
vaccine development is under-funded without prospect of an
efficacious vaccine in the near future [9,33,37]. A vaccine
Table 1. Congenital CMV-related deaths by sex, race, and region with corresponding age-adjusted mortality rates in the United
States, 1990–2006.
Variable Congenital CMV related deaths, n (%) Age adjusted mortality rate per 1 million person years, rate (95% CI)
All 777 (100%) 0.16 (0.15, 0.17)
Sex
Male 340 (43.8%) 0.15 (0.13, 0.16)
Female 437 (56.2%) 0.18 (0.16, 0.19)
Race
Asian 15 (1.9%) 0.08 (0.04, 0.12)
African American 199 (25.6%) 0.27 (0.23, 0.31)
Hispanic 123 (15.8%) 0.14 (0.11, 0.16)
Native American 15 (1.9%) 0.34 (0.17, 0.51)
White 425 (54.7%) 0.14 (0.13, 0.16)
Region
Northeast 82 (10.6%) 0.10 (0.10, 0.12)
West 186 (23.9%) 0.16 (0.14, 0.19)
Midwest 183 (23.6%) 0.17 (0.15, 0.19)
South 326 (42.0%) 0.19 (0.17, 0.21)
doi:10.1371/journal.pntd.0001140.t001
Table 2. Frequencies and rate-ratios of congenital CMV-related death by race in the United States, 1990–2006.
Race Total Deaths
Rate Ratios (whites reference
group)
Lower 95% Confidence
Interval
Upper 95% Confidence
Interval
Asian 15 (1.9%) 0.54 0.44 0.66
African American 199 (25.6%) 1.89 1.70 2.11
Hispanic 123 (15.8%) 0.96 0.83 1.10
Native American 15 (1.9%) 2.34 2.11 2.59
White 425 (54.7%) referent
doi:10.1371/journal.pntd.0001140.t002
Congenital CMV Mortality in the US, 1990–2006
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prevention of congenital CMV and may offer further reaching
benefits given the burden of disease caused by CMV extends
beyond those congenitally infected [38].
Several important limitations are associated with the use of
multiple-cause-of-death data that require consideration. Although
these data are population based and contain large numbers of
observations, death certificates may contain errors, which have
been attributed to a variety of factors [39,40]. The interpretation
of cause of death as underlying versus contributing on the death
certificate has not been rigorously evaluated [41]. Further, the
interpretation of position of the causes is difficult, especially given
changes to the original coding by NCHS software.
Underreporting of congenital CMV infections may also limit
our study. In order to receive a death certificate, criteria for
obtaining a birth certificate must first be met. Congenital CMV
infected fetuses that do not survive to live birth are not represented
in our data. Furthermore, we have identified over 450 non-
congenital CMV-associated deaths in infants in our dataset over
the study period, which may contain misclassified congenital
CMV-associated cases (data not shown).
In the setting of a severely ill infant, it may be difficult to
distinguish an incidental congenital CMV infection from congen-
ital CMV disease. Misclassification on the death certificate could
occur if a severely ill infant expired and the physician incorrectly
believed the incidental infection to represent disease contributing
to death. Unfortunately, we do not have the data that would be
necessary to address or estimate the magnitude of this specific bias.
Mortality rates may be distorted because of errors in population
estimates, particularly for race/ethnicity. Because estimates of the
at-risk population factor into the denominator for rate calcula-
tions, such errors can lead to biased estimates. In addition, the
small numbers of congenital CMV-related deaths in Native
Americans and Asians makes interpretation difficult. Finally,
although inferential statistics are not designed for use with
population-based data, we have used such methods in order to
demonstrate that error does exist within our likelihood ratios. We
urge caution in the strict interpretation of our values.
Any efforts to measure the burden of congenital CMV mortality
would benefit from having maternal data, however such
information is not available in the national multiple cause of
death files. Linked birth – infant death data for the US are
available from National Center for Health Statistics for selected
years and contain valuable information including mother’s age,
access to prenatal care, gestational age and birth weight; however,
only underlying cause of death is provided. Nevertheless, such
analyses may provide added insights that are not available from
mortality data alone.
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